Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PIK3CD antisense RNA 2 (PIK3CD-AS2)
- Target
- PIK3CD-AS2
- Molecular classification
- Long non-coding RNA (lncRNA), Antisense RNA, Other (non-protein-coding regulatory RNA)
01
Overview
PIK3CD antisense RNA 2 (PIK3CD-AS2) is a cytoplasmic long non-coding RNA transcribed antisense to the PIK3CD gene. It regulates cellular processes by modulating the stability of YBX1, a negative regulator of p53, thereby suppressing p53 signaling and promoting cell proliferation while inhibiting apoptosis. PIK3CD-AS2 is upregulated in lung adenocarcinoma, especially in p53 wild-type contexts, and is associated with poor patient prognosis. Preclinical inhibition of PIK3CD-AS2 using locked nucleic acid oligonucleotides exhibits tumor suppressive effects. Beyond cancer, PIK3CD-AS2 is differentially expressed in human brain tissue and patient-derived cells from schizophrenia, particularly in fetal brain, implicating it in neurodevelopmental regulatory networks. Additionally, it has been shown to interact with viral proteins such as H5N1-NS1, highlighting potential relevance in infection biology
- Other names
- PIK3CD-AS2PIK3CD AS2long non-coding RNA PIK3CD-AS2ENSG00000231789
02
Mechanism of action
Downregulation of PIK3CD-AS2 by RNA-based agents restores p53 tumor suppression activity and inhibits tumor growth
03
Biological functions
Regulation of gene transcriptionModulation of cell proliferationInhibition of apoptosisRegulation of p53 signalingModulation of Y-box binding protein 1 (YBX1) stability
04
Disease associations
Cancer (particularly lung adenocarcinoma)Neurodevelopmental disorder (schizophrenia)Infection (viral interaction; H5N1 influenza)
05
Safety considerations
Unknown (No clinical-stage data; theoretical risks include off-target RNA interference and systemic immune reactions to nucleic acid therapeutics)
06
Interacting drugs
Locked nucleic acid (LNA) oligonucleotide targeting PIK3CD-AS2 (preclinical anti-tumor agent)
1 more in the full profile.
07
Biomarkers
High PIK3CD-AS2 expression (biomarker for poor disease-free survival in p53 wild-type lung adenocarcinoma)Potential biomarker for schizophrenia risk and developmental brain status
Beyond the preview
Go deeper on PIK3CD antisense RNA 2 (PIK3CD-AS2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PIK3CD antisense RNA 2 (PIK3CD-AS2).